Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland

Flyfishingstocks Jan. 27 at 2:54 AM

$AMRN Normal bearish breathing...

0 · Reply

SanDiegoLiving Jan. 26 at 9:41 PM

$AMRN What people are feeling today isn’t random frustration. It’s a classic late-stage setup. When a stock repeatedly looks ready to break out and then gets pushed back down, it doesn’t mean the thesis is broken. It means price discovery is being contained. Low volume, tight ranges, and sharp sell pressure near obvious technical levels are exactly what you see when volatility is being managed, not when fundamentals are deteriorating. In real strategic processes, especially when bankers are involved, stability matters more than momentum. Every dollar of premature repricing weakens negotiating leverage and introduces risk. So the stock sits pinned and boring while valuation work happens behind closed doors. That’s why it feels buried every time it tries to move. Breakouts don’t happen when everyone expects them. They happen when the reason for containment disappears ⏳

2 · Reply

bennfine Jan. 26 at 8:07 PM

$AMRN what the heck today? like the stock is under the huge pile of snow at the end of my driveway.

0 · Reply

Md80dog Jan. 26 at 6:49 PM

$AMRN stock price was $7 pre reverse split when JT retired.

1 · Reply

kemah Jan. 26 at 6:25 PM

$AMRN Reminder: Alex Denner / Sarissa Capital effectively took control of Amarin in Feb–Mar 2023 after winning the special meeting and forcing multiple board resignations. Stock was ~$2.00/share at the time. Today, on a split-adjusted / comp-adjusted basis, it trades around $0.78 — down ~61% over the period he’s been in control. I was fully convinced he was the right activist for this situation. At this point, the numbers don’t support that thesis.

1 · Reply

Md80dog Jan. 26 at 5:11 PM

$AMRN the runway is what matters. We have no threat of COH at this point. In fact it is rising. Wait and watch what occurs after two or three quarters of reported profit. Not new molecule or use or study. Profit profit profit

0 · Reply

thisguysfalling Jan. 26 at 4:41 PM

$AMRN Frustrating! Every time it looks like we’re going to break out we get whacked back down. There’s definitely some manipulation involved here IMO. Hopefully we break out this year sometime otherwise I’ll be selling come year end.

1 · Reply

bennfine Jan. 26 at 4:05 PM

$AMRN why the low volume fade today??

0 · Reply

DoMoreCharity Jan. 26 at 12:30 PM

$AMRN https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1699492/full

1 · Reply

WiseSolution Jan. 26 at 10:54 AM

$AMRN noticed charles schwab wont let you buy online must call broker .. not sure why?

1 · Reply

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Jan 9, 2026, 7:00 AM EST - 17 days ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Nov 9, 2025, 4:15 PM EST - 2 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 3 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Oct 29, 2025, 10:21 AM EDT - 3 months ago

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 8:00 AM EDT - 3 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Sep 29, 2025, 5:52 PM EDT - 4 months ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Aug 31, 2025, 8:30 AM EDT - 5 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 5 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 5 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 6 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 6 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 6 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 7 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 9 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 9 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 9 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 10 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 10 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 10 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 11 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 11 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 11 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 11 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 2 years ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Flyfishingstocks Jan. 27 at 2:54 AM

$AMRN Normal bearish breathing...

0 · Reply

SanDiegoLiving Jan. 26 at 9:41 PM

2 · Reply

bennfine Jan. 26 at 8:07 PM

$AMRN what the heck today? like the stock is under the huge pile of snow at the end of my driveway.

0 · Reply

Md80dog Jan. 26 at 6:49 PM

$AMRN stock price was $7 pre reverse split when JT retired.

1 · Reply

kemah Jan. 26 at 6:25 PM

1 · Reply

Md80dog Jan. 26 at 5:11 PM

0 · Reply

thisguysfalling Jan. 26 at 4:41 PM

1 · Reply

bennfine Jan. 26 at 4:05 PM

$AMRN why the low volume fade today??

0 · Reply

DoMoreCharity Jan. 26 at 12:30 PM

$AMRN https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1699492/full

1 · Reply

WiseSolution Jan. 26 at 10:54 AM

$AMRN noticed charles schwab wont let you buy online must call broker .. not sure why?

1 · Reply

rdhitchcock Jan. 24 at 9:59 PM

$AMRN One of the key takeaways from the study: "While DHA is vital for brain health, non DHA fatty acids like EPA showed an even stronger protective association, likely due to their anti-inflammatory effects." Don't forget to take your Vascepa today. :-) https://www.nutritioninsight.com/news/omega-3-early-onset-dementia-brain-supplements.html

1 · Reply

framus_morrigan Jan. 24 at 9:50 AM

$AMRN Potential iHS pattern completed. If the gods are benevolent then the breakout will only be a matter of time. GL

1 · Reply

bellingheimster Jan. 24 at 12:07 AM

$AMRN I wonder if covidshitforbrains finally threw in the towel here? Haven't seen one of their brilliant, mind bending intellectual posts for some time. Talk about a fetish for all things poo...yeesh, what a bozo. Hopefully they're getting the professional help they need to get out of their parents basement.

1 · Reply

TraderRapp Jan. 23 at 9:24 PM

$AMRN anyone else see a nearly perfect iHS on the 3-month chart? I am tired so.. @framus_morrigan

1 · Reply

declanaidan Jan. 23 at 9:10 PM

$AMRN Disappointing fade into the close, but still up over 9% for the week. Dow, Nasdaq, S&P all down on the week. Enjoy the weekend!

1 · Reply

CaptBeer Jan. 23 at 9:01 PM

BEER GOOD $AMRN GOOD. Have a great weekend!

0 · Reply

yevrag Jan. 23 at 8:16 PM

$AMRN dog shit can’t hold that tells me this is gonna tank next week!

0 · Reply

OGbobbypoppin Jan. 23 at 7:23 PM

$DKNG the ironic part is prediction markets can be manipulated just like sports betting, except there’s even less regulation around them lol outlaw sports betting and the prediction markets will become the wild Wild West Check out $AMRN if you’re into healthcare and undervalued pharma company

0 · Reply

Family23 Jan. 23 at 4:52 PM

$AMRN

0 · Reply

TomorrowIsANewDay Jan. 23 at 4:45 PM

$AMRN @lillylang

1 · Reply

ians Jan. 23 at 3:56 PM

$AMRN Good recap of Amarin's case. SCOTUS should just affirm FC ruling & slap Hikma with punitive damages IMHO 👍☘️💎 " Hikma's....press releases consistently characterized their drug as being a "generic equivalent to Vascepa®" and cite the SH indication limitation as being only a part of their approved indication. These implications were supported by reports on sales figures resulting in large (75%) part from off-label use for CV indications. "Those allegations, taken together with those relating to Hikma's label, at least plausibly state a claim for induced infringement," the Court held." "The opinion disdainfully rejects Hikma's "inflated characterizations" regarding the dire consequences for section viii carve-outs should the Court rule (as it does) against them." https://www.jdsupra.com/legalnews/amarin-pharma-inc-v-hikma-5369462/

1 · Reply

SanDiegoLiving Jan. 23 at 1:45 PM

$AMRN ⏳

3 · Reply

Market Cap	338.09M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	89,300
Avg Vol	94,900
Day's Range	N/A - N/A
Shares Out	20.79M
Stochastic %K	37%
Beta	0.72
Analysts	Hold
Price Target	$12.00